Table 2 Changes in cardiometabolic risk measures
Study 1 | Study 2 | |||||
|---|---|---|---|---|---|---|
Tirzepatide | Placebo | ETD | Tirzepatide | Placebo | ETD | |
Change in SBP (mmHg) from baseline at week 48 | −9.6 ± 1.1*** | −1.7 ± 1.1 | −7.9 (−11.0 to −4.9)*** † | −7.6 ± 1.1*** | −3.3 ± 1.2** | −4.3 (−7.3 to −1.2)** † |
Change in DBP (mmHg) from baseline at week 48 | −5.2 ± 0.8*** | −2.0 ± 0.8* | −3.2 (−5.4 to −1.0)** † | −3.0 ± 0.7*** | −1.8 ± 0.8* | −1.2 (−3.4 to 0.9) † |
Percent change in hsCRP from baseline at week 52 | −44.2 ± 4.4*** | −21.4 ± 6.6** | −28.9 ± 8.2** | −50.7 ± 4.8*** | −10.4 ± 9.8 | −45.1 ± 8.0*** |
Percent change in HDL-C from baseline at week 52 | 10.6 ± 1.5*** | 3.1 ± 1.5* | 7.2 ± 2.1*** | 15.0 ± 2.0*** | 4.5 ± 2.0* | 10.0 ± 2.8*** |
Percent change in non-HDL-C from baseline at week 52 | −15.0 ± 2.1*** | −2.3 ± 2.5 | −13.0 ± 3.1*** | −15.8 ± 1.6*** | −1.8 ± 2.1 | −14.3 ± 2.5*** |
Percent change in triglycerides from baseline at week 52 | −32.9 ± 2.6*** | −1.0 ± 4.0 | −32.2 ± 3.8*** | −35.2 ± 2.3*** | −5.4 ± 3.8 | −31.5 ± 3.7*** |
Percent change in LDL-C from baseline at week 52 | −8.9 ± 2.7** | −4.3 ± 3.0 | −4.8 ± 4.2 | −10.2 ± 2.0*** | 0.0 ± 2.5 | −10.3 ± 3.0** |
Percent change in VLDL-C from baseline at week 52 | −32.4 ± 2.5*** | 0.3 ± 3.9 | −32.6 ± 3.7*** | −34.9 ± 2.3*** | −5.0 ± 3.8 | −31.4 ± 3.7*** |
Percent change in fasting insulin from baseline at week 52 | −44.2 ± 3.3*** | −4.7 ± 5.9 | −41.4 ± 5.0*** | −48.5 ± 3.4*** | −5.6 ± 6.9 | −45.4 ± 5.4*** |
Percent change in HOMA-IR from baseline at week 52 | −51.2 ± 3.2*** | −6.2 ± 6.4 | −48.0 ± 4.9*** | −55.8 ± 3.3*** | −2.7 ± 7.9 | −54.5 ± 5.0*** |
